Project 3: lncRNA SNHG1 and ATG7 in Basal-subtype Muscle-invasive Bladder Tumorigenesis
项目3:lncRNA SNHG1和ATG7在基底亚型肌侵袭性膀胱肿瘤发生中的作用
基本信息
- 批准号:10661067
- 负责人:
- 金额:$ 33.43万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-09-12 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:AblationAutophagocytosisBIRC4 geneBiologicalBiological MarkersBiological ProcessBladderCD44 geneCRISPR/Cas technologyCarcinogensCatabolismCell modelCellsCharacteristicsChemicalsClassificationDataEctopic ExpressionExposure toFundingGenesGoalsHumanIn VitroInvadedKnock-in MouseKnock-outKnockout MiceLoxP-flanked alleleMMP2 geneMMP9 geneMalignant NeoplasmsMalignant neoplasm of urinary bladderMediatingMediatorMolecularMusMuscleNeoplasm MetastasisNitrosaminesPathway interactionsPhenotypePlayPrognostic MarkerRNAResistanceResourcesRoleSignal PathwaySignal TransductionSignaling MoleculeSmall Nucleolar RNAStratificationSystemTestingTransgenic MiceTransgenic OrganismsUntranslated RNAUp-RegulationUrothelial CellVariantXenograft Modelcancer biomarkerscancer cellcancer subtypescarcinogenesiseffective therapyin vivoinhibition of autophagyinhibitorknock-downmolecular subtypesmortalitymuscle invasive bladder cancernew therapeutic targetnon-muscle invasive bladder cancernoveloverexpressionpromotersmall hairpin RNAtumor progressiontumorigenesis
项目摘要
PROJECT 3: SUMMARY
The major goal of this project is to study the molecular mechanisms that underlie the critical steps of bladder
cancer (BC) progression: invasion and metastasis. Specifically, we will focus on how autophagy-related gene 7
(ATG7)-mediated autophagy signaling drives BC cell invasion in vitro and metastasis in vivo. During the last
funding period, we found that basal-subtype muscle-invasive bladder cancer (MIBC) in mice induced by bladder
carcinogen N-butyl-N-(4-hydroxybutyl) nitrosamine (BBN) markedly overexpress ATG7 and long non-coding
RNA (lncRNA) small nucleolar RNA host gene 1 (SNHG1), and have significantly upregulated autophagy. In
stark contrast, knockin mice lacking the RING domain of XIAP, which are completely resistant to BBN-induced
basal MIBCs, have markedly reduced autophagy. We also found that, during BBN-mediated bladder
tumorigenesis, the RING domain of XIAP is essential for SNHG1 overexpression, and that ectopic expression of
SNHG1 in vitro induces autophagy and promotes BC cell invasion accompanied by upregulated ATG7, MMP2
and MMP9. Furthermore, we showed that knockdown of ATG7 strongly inhibits autophagy, abolishes BC cell
invasion and reduces the expression of basal MIBC marker KRT14. These data reveal a heretofore unknown
role of autophagy in basal MIBC formation. Based on these data, we hypothesize that the upregulation of SNHG1
and ATG7 by the RING domain of XIAP, and the autophagic signaling that these molecules trigger play critical
roles in the genesis and progression of basal MIBC. We will test this hypothesis in three Specific Aims. Aim 1
will define the regulatory circuitry in the SNHG1/ATG7/autophagy signaling axis that is operative in basal MIBC
in vitro. Aim 2 will determine the biological effects of the SNHG1/ATG7/autophagy signaling on BC cell invasion
in vitro and tumorigenesis and metastasis in vivo. Aim 3 will test the hypotheses that overexpression of SNHG1
in basal urothelial cells of transgenic mice promotes basal MIBC formation, and that ablation of ATG7 in these
cells of knockout mice renders mice resistant to basal MIBC formation and progression. These complementary
approaches will provide definitive evidence regarding the in vivo roles of SNHG1 and ATG7 in the formation and
progression of basal MIBC. While invasion and metastasis are the main reasons of the high mortality caused by
MIBC, very little is known about the principal molecules or pathways that drive these crucially important biological
processes. Our proposed studies that are highly focused on an important, but poorly understood signaling
pathway comprising SNHG1/ATG7/autophagy should yield critical information on not only the underlying
mechanisms, but also novel prognostic biomarkers to differentiate MIBC subtypes and new druggable targets to
treat this aggressive form of BC.
项目3:总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
DIANE M SIMEONE其他文献
DIANE M SIMEONE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('DIANE M SIMEONE', 18)}}的其他基金
Biomarker Validation in Pancreatic Cystic Neoplasms
胰腺囊性肿瘤的生物标志物验证
- 批准号:
10722347 - 财政年份:2023
- 资助金额:
$ 33.43万 - 项目类别:
POLQ Synthetic Lethality in HR-Deficient Pancreatic Adenocarcinoma
HR 缺陷型胰腺癌中的 POLQ 综合致死率
- 批准号:
10218126 - 财政年份:2020
- 资助金额:
$ 33.43万 - 项目类别:
POLQ Synthetic Lethality in HR-Deficient Pancreatic Adenocarcinoma
HR 缺陷型胰腺癌中的 POLQ 综合致死率
- 批准号:
10442427 - 财政年份:2020
- 资助金额:
$ 33.43万 - 项目类别:
POLQ Synthetic Lethality in HR-Deficient Pancreatic Adenocarcinoma
HR 缺陷型胰腺癌中的 POLQ 综合致死率
- 批准号:
10656484 - 财政年份:2020
- 资助金额:
$ 33.43万 - 项目类别:
2015 Pancreatic Diseases Gordon Research Conference
2015年胰腺疾病戈登研究会议
- 批准号:
8970783 - 财政年份:2015
- 资助金额:
$ 33.43万 - 项目类别:
Project 3: lncRNA SNHG1 and ATG7 in Basal-subtype Muscle-invasive Bladder Tumorigenesis
项目3:lncRNA SNHG1和ATG7在基底亚型肌侵袭性膀胱肿瘤发生中的作用
- 批准号:
10229414 - 财政年份:2013
- 资助金额:
$ 33.43万 - 项目类别:
Project 3: lncRNA SNHG1 and ATG7 in Basal-subtype Muscle-invasive Bladder Tumorigenesis
项目3:lncRNA SNHG1和ATG7在基底亚型肌侵袭性膀胱肿瘤发生中的作用
- 批准号:
10455731 - 财政年份:2013
- 资助金额:
$ 33.43万 - 项目类别:
P4 - ATDC as a Therapeutic Target in Pancreatic Cancer
P4 - ATDC 作为胰腺癌的治疗靶点
- 批准号:
7893337 - 财政年份:2010
- 资助金额:
$ 33.43万 - 项目类别: